Pieris Pharmaceuticals

Pieris Pharmaceuticals is a clinical stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. Anticalin proteins are currently used as research tools. Diagnostic and therapeutic applications, including the use for targeted drug delivery, are being aimed at.

Company Growth (employees)
Boston, US
Size (employees)
49 (est)+29%
Pieris Pharmaceuticals was founded in 2001 and is headquartered in Boston, US

Pieris Pharmaceuticals Office Locations

Pieris Pharmaceuticals has an office in Boston
Boston, US (HQ)
255 State St

Pieris Pharmaceuticals Data and Metrics

Pieris Pharmaceuticals Financial Metrics

Pieris Pharmaceuticals's revenue was reported to be $1.3 m in Q1, 2017

Revenue (Q1, 2017)

1.3 m

Net income (Q1, 2017)

(8 m)

EBIT (Q1, 2017)

(8 m)

Market capitalization (19-Sep-2017)

234 m

Cash (31-Mar-2017)

55.2 m
Pieris Pharmaceuticals's current market capitalization is $234 m.
USDFY, 2014FY, 2015FY, 2016


5.4 m2.9 m5.8 m

Revenue growth, %


R&D expense

5.6 m8.2 m19.7 m

General and administrative expense

7 m8.4 m8.9 m
USDQ1, 2015Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017


217.6 k160.2 k414.6 k1.2 m1.1 m785 k1.3 m

R&D expense

1.5 m1.7 m2.1 m3.7 m4.5 m4.6 m5.4 m

General and administrative expense

2.4 m2 m2.2 m2 m2.4 m2.3 m4 m

Operating expense total

3.9 m3.7 m4.3 m5.6 m6.9 m7 m9.3 m
USDFY, 2014FY, 2015FY, 2016


18.5 m29.3 m29.4 m

Accounts Receivable

5.7 m99557.6 k


2.3 m3.3 m

Current Assets

19.8 m31.7 m32.7 m
USDQ1, 2015Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017


13.2 m10 m32.3 m31.2 m40.4 m36.6 m55.2 m

Accounts Receivable

39 k

Current Assets

15 m12.6 m34.2 m34.9 m43.9 m41.1 m58.8 m


1.8 m1.8 m1.9 m2.2 m2.4 m2.4 m3 m
USDFY, 2014FY, 2015FY, 2016

Net Income

(9.8 m)(14.1 m)(22.8 m)

Depreciation and Amortization

367 k307.9 k361.4 k

Accounts Receivable

465.4 k465.4 k(58.7 k)


4 k(136.3 k)127.5 k
USDQ1, 2015Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(13.9 k)(3.7 m)(3.5 m)(3.9 m)(4.2 m)(5.9 m)(6.2 m)(8 m)

Accounts Receivable

17.4 k70.3 k39 k

Accounts Payable

1.5 m2.1 m1.1 m1.7 m1.6 m4.5 m3.3 m

Cash From Operating Activities

(13.9 k)
USDY, 2017


30.9 k

Financial Leverage

3.4 x
Show all financial metrics

Pieris Pharmaceuticals Market Value History

Traffic Overview of Pieris Pharmaceuticals

Pieris Pharmaceuticals News and Updates

BRIEF-Pieris Pharma announces resale of upto 13.1 mln shares by selling stockholders

* Resale of up to 13.1 million shares of common stock by the selling stockholders - SEC Filing Source text - http://bit.ly/29DPuu3 Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Pieris Pharmaceuticals Company Life and Culture

You may also be interested in